
|Videos|August 13, 2015
Dr. Shannon Puhalla on PALOMA-3 Updates
Author(s)Shannon Puhalla, MD
Shannon Puhalla, MD Assistant Professor of Medicine, Division of Hematology, University of Pittsburgh, discusses recent updates of the PALOMA-3 trial.
Advertisement
Shannon Puhalla, MD, assistant professor of Medicine, University of Pittsburgh, discusses recent updates of the PALOMA3- trial.
PALOMA-3 was a phase III trial of targeted drug palbociclib in combination with hormone therapy fulvestrant in women with relapsed, metastatic hormone receptor-positive, HER2-negative breast cancer.
The study found a 6-month improvement in progression-free survival (PFS) with palbociclib. There were high rate of neutropenia with palbociclib compared to fulvestrant alone.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5




































